News | June 09, 2026
FUJIFILM reshapes life sciences leadership to accelerate cell therapy and iPSC expansion
Tomoyuki Hasegawa has been appointed CEO of FUJIFILM Biotechnologies California
Tomoyuki Hasegawa has been appointed CEO of FUJIFILM Biotechnologies California
Shoreline has developed a proprietary methodology to create differentiated iNK cells for large-scale, "off-the-shelf" production
New Tracxn report highlights growing investor confidence in automated cell therapy production, with Cellares and Ori Biotech dominating funding and regulatory milestones
Mahler brings more than 20 years of leadership experience spanning cell therapy, biopharmaceutical development, manufacturing, and global business management
The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
Several technologies for hemoglobinopathies are being transferred to commercial partners
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
